Medidata to Sponsor Lazarex Cancer Foundation’s Disrupting the System Annual Summit
June 14, 2022— Medidata, a Dassault Systèmes company, is partnering with the Lazarex Cancer Foundation to host and sponsor their annual Disrupting the System Summit. The 5th annual Summit, which will be held virtually June 15, 5 – 7 p.m. ET, brings together disruptors, innovators and change makers in oncology and patient advocacy. Free tickets to the virtual event are available online.
“This event seeks to unite participants in a common goal: to search for solutions to better level the playing field when it comes to cancer health disparities, patient access and cancer health outcomes,” said Dana Dornsife, Lazarex Cancer Foundation founder. “We’re grateful for the support Medidata provides, which translates into assistance with costs for FDA clinical trial participation, identification of clinical trial options, and support for community outreach and engagement.”
Medidata supports the Lazarex Foundation in addressing the obstacles cancer patients face in clinical trial participation and their work to explore real solutions. This event allows for conversations with some of the biggest innovators in oncology and patient advocacy to spark change, improve health outcomes, and make cancer research accessible to all.
Among these innovators is Alicia Staley, vice president, Patient Engagement at Medidata: “As a three-time cancer survivor, I have devoted my career to improving the patient experience for those fighting cancer, and recognize the importance of having a healthcare system that works for all patients. I look forward to discussing how we can create an ecosystem that provides high-quality care for patients of all backgrounds.”
The event will consist of two panels:
The Dirty Little Secret in Healthcare: How Insurance Impacts Your Cancer Journey When people are diagnosed with cancer, their ability to access treatment and surgeries more often comes down to the type of insurance they have. This panel will delve into how often this happens, what it means for patients and, most importantly, what can be done to change it.
- Sharrelle Barber ScD, MPH - assistant professor, director of The Ubuntu Center on Racism, Global Movements, and Population Health Equity, Drexel University
- Jane Garcia MPH, CEO, Clínica de la Raza Cancer Care
- Jeanne Regnante - strategic health equity advisor, Tigerlily Foundation, Founder & CEO, Patient 3i, LLC
- Richard N. Gottfried, member, New York State Assembly
Reporting Cancer Clinical Trial Patient Participation: Why FDA Guidance is Not Enough
The FDA does not currently mandate reporting of race and ethnicity in clinical trials. Lack of this participant data results in the absence of information on risks and side effects for patients of color, even for treatment of cancers that predominantly affect patients of color. This panel will explore what is happening now and what can be done to ensure that all drugs are safe, effective and equitable for everyone.
- Alicia Staley - vice president of Patient Engagement, Medidata
- Rhonda Long, a cancer patient voice
- Dr. Marya Shegog - health equity and diversity director at the Lazarex Foundation
Also during the event, special Lazarex Disruptor Awards will be presented to Senator Bob Menendez and Freddie Muse, Founder and CEO of The Men's Cancer Network Inc.
Senior Director, Corporate Communications & Affairs
External Communications Director